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ORIGINAL RESEARCH
Association of Heart Failure With Outcomes 
Among Patients With Peripheral Artery 
Disease: Insights From EUCLID
Marc D. Samsky , MD; Anne Hellkamp, MS; William R. Hiatt , MD; F. Gerry R. Fowkes, MBChB, PhD;  
Iris Baumgartner, MD; Jeffrey S. Berger , MD, MSc; Brian G. Katona , PharmD; Kenneth W. Mahaffey, MD; 
Lars Norgren , MD, PhD; Juuso I. Blomster, MD, PhD; Frank W. Rockhold , PhD; Adam D. DeVore , MD, 
MHS; Manesh R. Patel, MD; W. Schuyler Jones , MD
BACKGROUND: Peripheral artery disease (PAD) and heart failure (HF) are each independently associated with poor outcomes. 
Risk factors associated with new- onset HF in patients with primary PAD are unknown. Furthermore, how the presence of HF 
is associated with outcomes in patients with PAD is unknown.
METHODS AND RESULTS: This analysis examined risk relationships of HF on outcomes in patients with symptomatic PAD ran-
domized to ticagrelor or clopidogrel as part of the EUCLID (Examining Use of Ticagrelor in Peripheral Arterial Disease) trial. 
Patients were stratified based on presence of HF at enrollment. Cox models were used to determine the association of HF 
with outcomes. A separate Cox model was used to identify risk factors associated with development of HF during follow- up. 
Patients with PAD and HF had over twice the rate of concomitant coronary artery disease as those without HF. Patients with 
PAD and HF had significantly increased risk of major adverse cardiovascular events (hazard ratio [HR], 1.31; 95% CI, 1.13– 1.51) 
and all- cause mortality (HR, 1.39; 95% CI, 1.19– 1.63). In patients with PAD, the presence of HF was associated with signifi-
cantly less bleeding (HR, 0.65; 95% CI, 0.45– 0.96). Characteristics associated with HF development included age ≥66 (HR, 
1.29; 95% CI, 1.18– 1.40 per 5 years), diabetes mellitus (HR, 1.85; 95% CI, 1.41– 2.43), and weight (bidirectionally associated, 
≥76 kg, HR, 0.77; 95% CI, 0.64– 0.93; <76 kg, HR, 1.12; 95% CI, 1.07– 1.16).
CONCLUSIONS: Patients with PAD and HF have a high rate of coronary artery disease with a high risk for major adverse car-
diovascular events and death. These data support the possible need for aggressive treatment of (recurrent) atherosclerotic 
disease in PAD, especially patients with HF.
Key Words: heart failure ■ outcomes ■ peripheral artery disease
Peripheral artery disease (PAD) and chronic heart failure (HF) are systemic diseases, each with an increasing incidence and repeatedly associated 
with progressive functional limitation as well as in-
creased morbidity and mortality.1– 5 Expectedly, PAD 
and HF often coexist in patients with atherosclerotic 
vascular disease.6,7 The presence of PAD has been 
associated with increased morbidity and mortality in 
patients with HF.8,9 However, the association of chronic 
HF with clinical and safety outcomes in patients with 
atherosclerotic vascular disease, particularly PAD, 
remains undefined. Several of the recently published 
clinical trials studying antiplatelet and antithrombotic 
therapies in patients with PAD do not report the base-
line rates of concomitant HF and are therefore unlikely 
to incorporate this important comorbidity into predic-
tion modeling for clinical or safety events.10– 13
The EUCLID (Examining Use of Ticagrelor in 
Peripheral Artery Disease) trial randomly assigned pa-
tients with symptomatic PAD to receive either ticagrelor 
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or clopidogrel to determine optimal antiplatelet therapy 
for patients with symptomatic PAD. We conducted this 
analysis to examine the association of HF with clinical 
outcomes and safety events in patients with PAD. We 
intended to identify a high- risk cohort of patients who are 
tolerant of guideline- directed medical therapy without an 
increased risk of harm. We hypothesized that compared 
with patients without HF, those with concomitant HF are 
at increased risk of adverse clinical outcomes. We further 
hypothesized that patients with HF would have no differ-
ence in rates of adverse outcomes and tolerance of an-
tiplatelet therapy without differences in rates of bleeding.
Finally, progressive atherosclerotic coronary artery 
disease (CAD) is the strongest risk factor for develop-
ment of HF.13– 16 We were also interested in identifying 
risk factors for development of HF (defined as HF- 
related death or HF hospitalization) in a cohort of pa-
tients with known atherosclerotic disease but without 
a high burden of concomitant CAD. We therefore used 
EUCLID, which uniquely included a relatively small pro-
portion of patients with CAD.
METHODS
Study Design and Population
The design and primary results of the EUCLID 
(NCT01732822) trial have been previously pub-
lished.12,17 EUCLID was a double- blind, multicenter, 
randomized controlled trial comparing the efficacy 
and safety of ticagrelor (90 mg twice daily) with clopi-
dogrel (75 mg once daily) for the treatment of major ad-
verse cardiovascular events (MACEs) in patients with 
symptomatic PAD. Inclusion criteria for EUCLID were 
as follows: (1) symptomatic PAD defined as an ankle- 
brachial index (ABI) ≤0.80 with claudication (n=6010) or 
(2) prior lower- extremity revascularization (n=7875). Key 
exclusion criteria were planned use of dual antiplate-
let therapy, requirement for aspirin, history of bleeding 
diathesis, treatment with anticoagulation, or poor me-
tabolizer status for cytochrome P450 2C19 (possess-
ing a known genotype of 2 loss- of- function alleles). A 
total of 13 885 patients were randomized and followed 
for all clinical end points and serious adverse events 
until the end of the study. For this analysis, a patient 
was included in the HF group if “prior congestive heart 
failure” was answered as “Yes” on the EUCLID case 
report form at the time of enrollment. Additional infor-
mation on HF findings and duration were not available.
All patients provided written informed consent. 
Institutional review boards at each participating center 
approved the protocol. The authors had access to all 
data and are responsible for statistical analysis, draft-
ing, critical review, content control, and submission of 
this article. The data that support the findings of this 
study are available from the corresponding author 
upon reasonable request.
End Points
The end points for this analysis were derived from the 
primary efficacy and safety end points of the EUCLID 
CLINICAL PERSPECTIVE
What Is New?
• Peripheral artery disease (PAD) and chronic 
heart failure (HF) are each independently asso-
ciated with adverse events and death, yet out-
comes for patients with both comorbidities are 
poorly defined.
• For patients with PAD, risk factors associated 
with development of de novo HF are unknown.
• This post hoc analysis of the EUCLID (Examining 
Use of Ticagrelor in Peripheral Arterial Disease) 
trial demonstrates that patients with PAD and HF 
have a high rate of concomitant coronary artery 
disease with an associated high risk for major 
adverse cardiovascular events and death; age, 
concomitant diabetes mellitus, and low weight 
were the strongest predictors of new HF for pa-
tients with PAD during follow- up in EUCLID.
What Are the Clinical Implications?
• These data support the possible need for ag-
gressive treatment of (recurrent) atherosclerotic 
disease in patients with PAD, especially those 
with concomitant HF.
Nonstandard Abbreviations and Acronyms
EUCLID Examining Use of 
Ticagrelor in Peripheral 
Artery Disease
HF- ACTION Heart Failure and a 
Controlled Trial 
Investigating Outcomes of 
Exercise Training
MACE major adverse 
cardiovascular event
MALE major adverse limb event
PEGASUS- TIMI 54 Prevention of 
Cardiovascular Events in 
Patients With Prior Heart 
Attack Using Ticagrelor 
Compared to Placebo on 
a Background of Aspirin– 
Thrombolysis in 
Myocardial Infarction 54
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trial. Efficacy end points included: MACE including 
combined cardiovascular death, myocardial infarction 
(MI), and ischemic stroke. Major adverse limb events 
(MALEs) were defined as a combination of major am-
putation and acute limb ischemia requiring hospitali-
zation. Patients were considered to have new- onset 
HF if they did not have HF at baseline and the patient 
died with the adjudicated cause of death as HF/car-
diogenic shock; the patient was hospitalized with a 
primary discharge diagnosis of HF (nonadjudicated); 
or the patient had a serious adverse event labeled 
as “heart failure signs and symptoms, left ventricular 
failure, or right ventricular failure.” Outcome analy-
ses, including development of new- onset HF, were 
conducted using the intention- to- treat population in 
EUCLID, and all events that occurred after randomi-
zation through the end of the study were included. 
Efficacy end points were measured from randomiza-
tion to the censoring date for the primary analysis or 
the date of last trial contact (whichever came first). 
Safety end points included TIMI (Thrombolysis in 
Myocardial Infarction) major bleeding and combined 
TIMI major and minor bleeding. In EUCLID, safety 
end points were measured during the on- treatment 
period plus an additional 7  days, unless treatment 
ended in patient death. Patients who died during this 
7- day follow- up period were censored at the time of 
death.
Statistical Methods
For descriptive summaries, all patients with data for 
history of HF were included (N=13  883). Categorical 
variables are presented as percentage counts and 
compared between groups with Pearson’s chi- 
squared tests. Continuous variables are presented as 
medians (Q1– Q3) and compared between groups with 
Wilcoxon rank- sum tests.
For the efficacy and safety outcomes Kaplan- 
Meier curves were created with patients stratified on 
the basis of HF status. To examine risk relationships 
of HF with outcomes, we used previously developed 
Cox models from EUCLID for the MACE, MALE, 
and major and minor bleeding outcomes.12,18 For 
all- cause hospitalization, an additional Cox model 
was created using predictors chosen on the basis of 
stepwise selection with significance level of P=0.05. 
Age, weight, kidney function, and ABI were fit using 
restricted cubic splines, consistent with the other 
models as part of EUCLID. Despite not being statis-
tically significant, treatment assignment was retained 
in all models.
Given the interest in ascertaining whether outcomes 
from EUCLID were modified by the presence of con-
comitant HF, we chose to test the interaction between 
presence of HF at baseline with previously identified 
significant predictors for each outcome. To achieve 
this, an additional Cox model was also used to assess 
a differential treatment effect between assigned treat-
ment in EUCLID and presence of HF. For all models, 
patients with complete covariate data (N=12 767) were 
included.
Among patients without HF at baseline and with 
complete covariate data (N=10 948), an additional Cox 
model was developed, using the same method as the 
model for all- cause hospitalization. For this model, the 
outcome was first hospitalization for HF. Predictors 
were again identified using stepwise selection with a 
prespecified significance cut point of P=0.05. Assigned 
EUCLID treatment remained in the model, regardless 
of significance level.
Rates of missing were low in EUCLID. Among the 
analysis cohort, for the 22 baseline variables (aside 
from randomized treatment) used or considered as 
covariates for ≥1 end points, rates of missing were 
weight, 3.8% (n=482); renal function, 3.1% (n=434); 
ABI, 1.7% (n=231); tobacco use, <1% (n=80), dia-
betes mellitus, <1% (n=1); and Rutherford classifi-
cation, <1% (n=1), for a total of 1116 patients (8%). 
Given these low rates, only complete cases were 
used in each model, which is consistent with previ-
ous EUCLID publications. Mean follow- up in EUCLID 
was 30.4 months.
RESULTS
Demographics and Associations With 
Clinical Outcomes
A total of 13  883 (99.9%) patients with completed 
details regarding history of HF were included from 
EUCLID. Demographics of patients according to 
whether they had a history of HF at the time of enroll-
ment are shown in Table 1. The average age of each 
group was 66  years, and there was no difference in 
sex between the groups. Patients with HF had signifi-
cantly worse renal function (estimated glomerular filtra-
tion rate, 69.4 versus 76.1; P<0.001) and significantly 
lower ABI compared with patients without HF (0.68 
versus 0.71; P<0.001). Patients with HF were more 
likely to have CAD (53.6% versus 25.1%; P<0.001), 
prior MI (39.7% versus 14.7%; P<0.001), carotid steno-
sis/revascularization (24.5% versus 16.6%; P<0.001), 
and polyvascular disease defined by >1 arterial bed 
(P<0.001). Patients with HF were more likely to enroll 
on the basis of ABI criteria (54.9%) rather than a history 
of lower- extremity revascularization (45.1%), while pa-
tients without HF were more likely to have undergone 
prior PAD revascularization procedures (58.6% prior 
revascularization versus 41.4% noninvasive criteria; 
P<0.001). Forty percent of patients with HF reported 
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Table 1. Baseline Characteristics by History of HF
Variable HF (n=1928) No HF (n=11 955) P Value
Randomized to ticagrelor, % 50.8 49.8 0.41
Age, y 66 (60– 73) 66 (60– 72) 0.02
Female, % 27.0 28.2 0.3
BMI 27.8 (24.8– 31.2) 26.6 (23.8– 29.9) <0.001
eGFR, mL/min per 1.73 m2 (MDRD) 69.4 (55.5– 83.9) 76.1 (61.1– 92.0) <0.001
Geographic region, % <0.001
Central/South America 6.7 13.5
Europe 71.8 51.1
Asia 3.8 12.8
North America 17.6 22.6
Inclusion criteria for randomization, 
%
<0.001
Prior revascularization 45.1 58.6
ABI or TBI criteria 54.9 41.4
ABI 0.68 (0.55– 0.77) 0.71 (0.58– 0.84) <0.001
Limb symptoms (Rutherford 
classification), %
<0.001
Asymptomatic (0) 10.5 20.1
Mild or moderate claudication 
(1/2)
49.2 54.1
Severe claudication (3) 32.2 21.8
Rest pain (4) 6.0 2.2
Distal ischemic ulcers (5) 1.8 1.4




Major amputation (above ankle) 2.7 2.4 0.35






No heart failure 3.6 97.1
Prior stroke, % 11.4 7.7 <0.001
Prior TIA, % 4.0 3.6 0.39
CAD, % 53.6 25.1 <0.001
Prior MI, % 39.7 14.7 <0.001
Carotid stenosis or carotid 
revascularization, %
24.5 16.6 <0.001






Diabetes mellitus, % 39.7 38.3 0.25
Hypertension, % 87.3 76.7 <0.001
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while 25% of patients without HF reported symptoms 
of Rutherford category ≥3. Discontinuation of the study 
drug was consistent in patients with HF compared with 
those without (26% versus 28%, respectively).
Crude event rates for the overall population and 
by HF status for each outcome are shown in Table 2. 
Associations of HF with clinical outcomes are shown 
in the Figure. Patients with HF had significantly in-
creased risk of experiencing MACE (hazard ratio [HR], 
1.31; 95% CI, 1.13– 1.51) and all- cause mortality (HR, 
1.39; 95% CI, 1.19– 1.63) compared with patients with-
out HF. There was a significantly increased risk of car-
diovascular death for patients with HF (HR, 1.59; 95% 
CI, 1.31– 1.92) and all- cause death (HR, 1.9; 95% CI, 
1.19– 1.63). Patients with HF had an increased risk of 
ischemic stroke and MI, though these did not meet the 
prespecified threshold for significance. Presence of HF 
was associated with significantly less combined TIMI 
major and minor bleeding (HR, 0.65; 95% CI, 0.45– 
0.96). The presence of HF was not significantly associ-
ated with risk of MALE (HR, 0.84; 95% CI, 0.60– 1.16).
Interaction Between Heart Failure and 
Predictors of MACE
Table 3 shows significant interactions between HF and 
baseline variables and outcomes of interest. There were 
3 variables (geographic region, weight, and ABI) signifi-
cantly associated with HF and clinical outcomes. When 
compared with North Americans, patients with HF from 
Central/South America and Europe had lower risk of 
MACE than patients without HF (HR, 0.51 versus 0.64; 
and HR, 0.51 versus 0.84, respectively). Compared with 
North Americans, patients from Asia with HF had higher 
risk of MACE compared with patients without HF (HR, 
0.75 versus 0.72) (interaction P=0.013).
We found a U- shaped relationship between weight 
and risk of MACE for patients with HF (HR, 0.90; 95% 
CI, 0.85– 0.96 per 5  kg up to 85  kg; and HR, 1.05; 
95% CI, 0.99– 1.12 per 5 kg above 85 kg). For patients 
without HF, there was consistently a decreased risk of 
MACE across all weights (HR, 0.96; 95% CI, 0.93– 1.00 
per 5 kg ≤85 kg; and HR, 1.01; 95% CI, 0.97– 1.05 per 
5 kg >85 kg) (Figure S1).
For patients with HF, risk of MACE decreased with 
increasing ABIs ≤0.6 (HR, 0.93; 95% CI, 0.82– 1.05 per 
ABI 0.1), at which point risk of MACE did not change 
(HR, 1.00; 95% CI, 0.92– 1.08). For patients without 
HF, there was an inverse relationship between risk of 
MACE and ABI (HR, 0.88; 95% CI, 0.82– 0.95 per 0.1 
≤ ABI 0.6; and HR, 0.95; 95% CI, 0.91– 0.99 >ABI 0.6) 
(Figure S2).
Interaction Between Heart Failure and 
Predictors of MALE
There were 3 significant interactions between HF 
and predictors of MALE (inclusion criteria, ABI, and 
Variable HF (n=1928) No HF (n=11 955) P Value
Tobacco use, % <0.001
Never 28.1 20.6
Former smoker 43.5 47.9
Current smoker 28.5 31.5, %
Medications within 30 d before randomization, %
Aspirin 67.1 66.7 0.74
Clopidogrel 34.8 31.8 0.01
ACE inhibitor 49.7 39.1 <0.001
Beta blocker 59.1 37.6 <0.001
ARB 23.5 25.4 0.09
Statin 77.0 72.7 <0.001
Cilostazol 7.5 16.3 <0.001
Covariates used for modeling. Cardiovascular death/MI/stroke: age, female, geographic region, weight, eGFR, inclusion criteria, ABI, Rutherford 
classification, previous major amputation, previous minor amputation, number of vascular beds, tobacco use, diabetes mellitus, prior MI, prior stroke, statin 
use. Cardiovascular death: age, female patient, weight, eGFR, ABI, Rutherford classification, major amputation, minor amputation, prior MI, prior stroke, ARB 
use, statin use. Ischemic stroke: age, region, Rutherford classification, minor amputation, tobacco use, prior stroke. MI: age, female patient, geographic region, 
eGFR, inclusion criteria, Rutherford classification, number of diseased vascular beds, tobacco use, prior percutaneous coronary intervention, prior MI, aspirin 
use. Death: age, female patient, geographic region, weight, eGFR, inclusion criteria, ABI, Rutherford classification, previous major amputation, previous minor 
amputation, diabetes mellitus, prior MI, prior stroke, ARB use, statin use. Major amputation/acute limb ischemia hospitalization: geographic region, weight, 
inclusion criteria, ABI, Rutherford classification, previous major amputation, previous minor amputation, diabetes mellitus, prior coronary artery bypass grafting, 
ARB use, statin use. Hospitalization: age, geographic region, weight, eGFR, inclusion criteria, ABI, Rutherford classification, previous minor amputation, number 
of vascular beds, prior carotid revascularization, tobacco use, diabetes mellitus, prior percutaneous coronary intervention, prior MI, prior stroke, randomized 
treatment assignment. Major bleed: age, female patient, geographic region, aspirin use. Combined major/minor bleed: age, female patient, geographic region, 
weight, inclusion criteria, ABI, Rutherford classification, aspirin use. ABI indicates ankle- brachial index; ACE, angiotensin- converting enzyme; ARB, angiotensin 
II receptor blocker; BMI, body mass index; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; HF, heart failure; MDRD, Modification of 
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angiotensin II receptor blocker use) (Table  3). There 
was an elevated risk of MALE based on inclusion 
criteria in EUCLID, which was less pronounced in 
patients with HF (HF HR, 1.43; 95% CI, 0.79– 2.58 ver-
sus no HF HR, 2.73; 95% CI, 2.06– 3.62; interaction 
P=0.048). We found a U- shaped relationship between 
risk of MALE and ABI for patients with HF (HR, 0.66; 
95% CI, 0.53– 0.82 per ABI, 0.1≤0.6 versus HR, 1.18; 
95% CI, 1.02– 1.38 per ABI 0.1>0.6). For patients with-
out HF, the risk of MALE decreased with increasing 
ABI until the threshold of ABI=0.6, after which the risk 
remained stable (HR, 0.71; 95% CI, 0.63– 0.79 per ABI 
0.1≤0.6 versus HR, 0.94; 95% CI, 0.87– 1.02 per ABI 
0.1>0.6). There was a significant interaction found be-
tween angiotensin II receptor blocker use before en-
rollment and presence of HF regarding MALE (HF HR, 
2.07; 95% CI, 1.11– 3.85 versus no HF HR, 0.66; 95% 
CI, 0.49– 0.89; interaction P=0.001) (Figure S3).
Interaction Between HF and Predictors of 
All- Cause Hospitalization
There were 3 significant interactions between HF 
and all- cause hospitalization (geographic region, ABI, 
and Rutherford score). When compared with North 
Americans, patients from Central/South America and 
Europe had a decreased risk of all- cause hospitaliza-
tion, regardless of HF. Patients from Asia had an in-
creased risk of all- cause hospitalization compared 
with North Americans, regardless of HF (interaction 
P<0.001). There was a U- shaped relationship between 
risk of all- cause hospitalization and ABI for patients 
with HF (HR, 0.93; 95% CI, 0.86– 1.01 per 0.1 ≤ ABI 
=0.6 versus HR, 1.03; 95% CI, 0.98– 1.08 per 0.1 > 
ABI=0.6). For patients without HF, the risk of hospitali-
zation decreased with increasing ABI (HR, 0.92; 95% 
CI, 0.88– 0.96 per 0.1 ≤ ABI=0.6 versus HR, 0.98; 95% 
CI, 0.96– 1.00 per 0.1 > ABI=0.6; interaction P=0.039) 
(Figure  S4). For patients without HF, compared with 
asymptomatic patients, increasing risk of all- cause 
hospitalization occurred with increasing Rutherford 
score (Rutherford score 1– 2: HR, 1.04; 95% CI, 0.96– 
1.13; 3: HR, 1.24; 95% CI, 1.12– 1.37; 4– 6: HR, 1.58; 
95% CI, 1.36– 1.84). This relationship was not present 
for patients with HF (Rutherford score 1– 2: HR, 0.99; 
95% CI, 0.79– 1.25; 3: HR, 1.17; 95% CI, 0.92– 1.48; 
4– 6: HR, 0.92; 95% CI, 0.66– 1.28; interaction P=0.012) 
(Table 3).
Table 2. Association of HF With Clinical and Safety Outcomes
Outcome
Events/100 Patient- Years (Total Events) Unadjusted Model Adjusted Model
All Patients HF No HF
HF vs No HF  
HR (95% CI) P Value
HF vs No HF  
HR (95% CI) P Value
Number 12 767 1819 10 948
Efficacy
MACE 4.41 (1350) 6.65 (279) 4.05 (1071) 1.63 (1.43– 1.87) <0.001 1.31 (1.13– 1.51) <0.001
Cardiovascular death 2.03 (644) 3.69 (162) 1.76 (482) 2.08 (1.74– 2.49) <0.001 1.59 (1.31– 1.92) <0.001
Ischemic stroke 0.88 (274) 1.18 (51) 0.83 (223) 1.45 (1.07– 1.97) 0.017 1.36 (0.99– 1.87) 0.058
MI 1.97 (610) 2.81 (119) 1.84 (491) 1.52 (1.25– 1.86) <0.001 1.20 (0.97– 1.48) 0.096
All- cause mortality 3.58 (1145) 5.35 (237) 3.30 (908) 1.62 (1.40– 1.87) <0.001 1.39 (1.19– 1.63) <0.001
MALE 1.13 (351) 1.07 (46) 1.14 (305) 0.93 (0.68– 1.26) 0.631 0.84 (0.60– 1.16) 0.288
Hospitalization 22.57 (5410) 25.00 (809) 22.19 (4601) 1.12 (1.04– 1.20) 0.004 1.06 (0.98– 1.15) 0.161
Safety
TIMI major bleed 0.75 (203) 0.50 (19) 0.79 (184) 0.61 (0.37– 0.99) 0.046 0.67 (0.41– 1.10) 0.112
TIMI major/minor bleed 1.26 (340) 0.79 (30) 01.33 (310) 0.59 (0.40– 0.86) 0.006 0.65 (0.45– 0.96) 0.030
Covariates used for modeling. Cardiovascular death/MI/stroke: age, female patient, geographic region, weight, eGFR, inclusion criteria, (ABI, Rutherford 
classification, previous major amputation, previous minor amputation, number of vascular beds, tobacco use, diabetes mellitus, prior MI, prior stroke, statin 
use. Cardiovascular death: age, female patient, weight, eGFR, ABI, Rutherford classification, major amputation, minor amputation, prior MI, prior stroke, ARB 
use, statin use. Ischemic stroke: age, region, Rutherford classification, minor amputation, tobacco use, prior stroke.MI: age, female patient, geographic region, 
estimated GFR, inclusion criteria, Rutherford classification, number of diseased vascular beds, tobacco use, prior percutaneous coronary intervention, prior 
MI, aspirin use. Death: age, female patient, geographic region, weight, eGFR, inclusion criteria, ABI, Rutherford classification, previous major amputation, 
previous minor amputation, diabetes mellitus, prior MI, prior stroke, ARB use, statin use. Major amputation/acute limb ischemia hospitalization: geographic 
region, weight, inclusion criteria, ABI, Rutherford classification, previous major amputation, previous minor amputation, diabetes mellitus, prior coronary artery 
bypass grafting, ARB use, statin use. Hospitalization: age, geographic region, weight, eGFR, inclusion criteria, ABI, Rutherford classification, previous minor 
amputation, number of vascular beds, prior carotid revascularization, tobacco use, diabetes mellitus, prior percutaneous coronary intervention, prior MI, 
prior stroke, randomized treatment assignment. Major bleed: age, female patient, geographic region, aspirin use. Combined major/minor bleed: age, female, 
geographic region, weight, inclusion criteria, ABI, Rutherford classification, aspirin use. ABI indicates ankle brachial index; ARB, angiotensin II receptor blocker; 
eGFR, estimated glomerular filtration rate; HF, heart failure; HR, hazard ratio; MACE, major adverse cardiovascular event (combined cardiovascular death, 
myocardial infarction, ischemic stroke); MALE, major adverse limb event (combined major amputation and acute limb ischemia requiring hospitalization); MI, 
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Development of New- Onset HF During 
Trial Follow- Up
Of the 10 948 patients from EUCLID without baseline HF 
and with complete covariate data present, 235 (0.87%) 
developed HF during follow- up. Table 4 lists charac-
teristics and event rates for development of new- onset 
HF during the EUCLID trial. Table  S1 includes event 
rates, unadjusted univariate model results, full model 
results, and final (selected) model results for all candi-
date predictors. The following clinical characteristics, 
listed in decreasing order of contribution to the model, 
were associated with development of new- onset HF: 
age, weight, presence of diabetes mellitus, previous 
MI, renal function, previous minor amputation, increas-
ing number of diseased vascular beds, increased 
Rutherford category, and major amputation were all 
associated with development of new- onset HF. Other 
variables that were assessed but dropped because of 
lack of significance included sex, geographic region, 
inclusion criteria, ABI, prior carotid revascularization, 
tobacco use, prior percutaneous coronary interven-
tion, prior coronary artery bypass grafting, prior stroke, 
and medication use before enrollment.
DISCUSSION
In this post hoc analysis from EUCLID, we present 
the largest and most contemporary analysis directly 
examining the added risk of HF on clinical outcomes 
in patients with PAD. There are several novel find-
ings of this analysis, which should be considered hy-
pothesis generating. First, patients with symptomatic 
PAD and concomitant HF were more likely to have 
an increased burden of vascular disease as well as 
a history of MI and stroke. Second, the presence of 
HF was potentially associated with increased risk of 
MACE and all- cause death but not MALE or hospitali-
zation. Finally, we identified increasing age, increas-
ing weight, diabetes mellitus, and known CAD as the 
clinical attributes most strongly associated with de-
velopment of postrandomization HF in patients with 
symptomatic PAD.
With regard to clinical outcomes of patients with 
PAD and HF, our findings build on data from the 
HF- ACTION (Heart Failure and a Controlled Trial 
Investigating Outcomes of Exercise Training) trial.19,20 In 
patients with chronic HF from HF- ACTION, PAD was an 
independent predictor of all- cause death or all- cause 
hospitalization.8 In the larger EUCLID trial, which was 
conducted in patients with PAD rather than patients 
with HF, those with PAD and concomitant HF had a 
significantly increased risk of MACE and all- cause 
mortality compared with patients with PAD in the ab-
sence of HF. Furthermore, there was a trend toward a 
significantly increased risk of ischemic stroke and MI in 
patients with HF. These results are potentially explained 
by the significantly increased burden of multibed ath-
erosclerotic cardiovascular disease, hypertension, and 
diabetes mellitus in the patients with PAD and HF. The 
Figure 1. Association of HF with outcomes.
Forest plot of HRs for history of HF for efficacy outcomes. ALI hosp indicates acute limb ischemia hospitalization; CV, cardiovascular; 
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significant interactions in geographic region with pres-
ence of HF on clinical outcomes may be explained by 
an increased prevalence of concomitant CAD in these 
regions. Efforts were made to limit enrollment of pa-
tients with known CAD in the United States to reduce 
overlap with the simultaneously enrolling PEGASUS- 
TIMI 54 (Prevention of Cardiovascular Events in Patients 
With Prior Heart Attack Using Ticagrelor Compared to 
Placebo on a Background of Aspirin– Thrombolysis in 
Myocardial Infarction 54) trial.
Objectively, patients with PAD and HF had sig-
nificantly worse measures of arterial disease, and 
a greater proportion of patients with HF had at least 
Rutherford category 3 claudication. Despite more ad-
vanced PAD in patients with HF, we did not identify a 
difference in MALEs between patients with and with-
out HF. This finding was somewhat surprising consid-
ering that patients with more advanced PAD have been 
shown to have increased rates of MALEs.1,5
We found that treatment with single antiplatelet 
agent therapy (clopidogrel or ticagrelor without the 
concomitant use of aspirin) in patients with PAD and 
HF was well tolerated. In fact, there was less combined 
TIMI major or minor bleeding in patients with PAD and 
HF compared with patients with PAD without HF. This 
is driven by the minor bleeding events, as there were 
no significant differences in TIMI major bleeding be-
tween patients with and without HF. The findings of 
no difference in MALEs and decreased bleeding in pa-
tients with PAD and HF are hypothesis generating and 
Table 3. Significant Interactions Between HF and Baseline Variables* for Risk of MACE, MALE, and All- Cause 
Hospitalization
HR Represents HF HR (95% CI) No HF HR (95% CI) Interaction P Value
MACE
Region† Central/South America vs North 
America
0.51 (0.30– 0.87) 0.64 (0.51– 0.80) 0.013
Europe vs North America 0.51 (0.38– 0.67) 0.81 (0.69– 0.94)
Asia vs North America 0.75 (0.44– 1.26) 0.72 (0.58– 0.90)
Weight (2- part spline) Per 5 kg, up to 85 kg 0.90 (0.85– 0.96) 0.96 (0.93– 1.00) 0.014
Per 5 kg, above 85 kg 1.05 (0.99– 1.12) 1.01 (0.97– 1.05)
ABI (2- part spline) Per 0.1, up to 0.6 0.93 (0.82– 1.05) 0.88 (0.82– 0.95) 0.042
Per 0.1, above 0.6 1.00 (0.92– 1.08) 0.95 (0.91– 0.99)
MALE
Inclusion criteria Revascularization vs ABI 1.43 (0.79– 2.58) 2.73 (2.06– 3.62) 0.048
ABI (2- part spline) Per 0.1, up to 0.6 0.66 (0.53– 0.82) 0.71 (0.63– 0.79) 0.026
Per 0.1, above 0.6 1.18 (1.02– 1.38) 0.94 (0.87– 1.02)
ARB Yes vs no 2.07 (1.11– 3.85) 0.66 (0.49– 0.89) 0.001
All- cause hospitalization
Region† Central/South America vs North 
America
0.75 (0.55– 1.01) 0.66 (0.59– 0.74) <0.001
Europe vs North America 0.62 (0.52– 0.74) 0.93 (0.86– 1.00)
Asia vs North America 1.34 (0.98– 1.83) 1.10 (1.00– 1.23)
ABI (2- part spline) Per 0.1, up to 0.6 0.93 (0.86– 1.01) 0.92 (0.88– 0.96) 0.039
Per 0.1, above 0.6 1.03 (0.98– 1.08) 0.98 (0.96– 1.00)
Rutherford Mild/moderate vs asymptomatic 0.99 (0.79– 1.25) 1.04 (0.96– 1.13) 0.012
Severe vs asymptomatic 1.17 (0.92– 1.48) 1.24 (1.12– 1.37)
Pain/ulcers vs asymptomatic 0.92 (0.66– 1.28) 1.58 (1.36– 1.84)
Covariates used for modeling. MACE: presence of HF, age, female patient, geographic region, weight, eGFR, inclusion criteria, ABI, Rutherford classification, 
previous major amputation, previous minor amputation, number of vascular beds, tobacco use, diabetes mellitus, prior MI, prior stroke, statin use, randomized 
treatment. MALE: major amputation/acute limb ischemia hospitalization: presence of HF, geographic region, weight, inclusion criteria, ABI, Rutherford 
classification, previous major amputation, previous minor amputation, diabetes mellitus, prior coronary artery bypass grafting, ARB use, statin use, randomized 
treatment. All- cause hospitalization: presence of HF, age, geographic region, weight eGFR, inclusion criteria, ABI, Rutherford classification, previous minor 
amputation, number of vascular beds, prior carotid revascularization, tobacco use, diabetes mellitus, prior percutaneous coronary intervention, prior MI, 
prior stroke, randomized treatment. ABI indicates ankle- brachial index; ARB, angiotensin II receptor blocker; eGFR, estimated glomerular filtration rate; 
EUCLID, Examining Use of Ticagrelor in Peripheral Artery Disease; HF, heart failure; HR, hazard ratio; MACE, major adverse cardiovascular event (combined 
cardiovascular death, myocardial infarction, ischemic stroke); MALE, major adverse limb event (combined major amputation and acute limb ischemia requiring 
hospitalization); MI, myocardial infarction; and TIMI, Thrombolysis in Myocardial Infarction.
*There were no significant interactions between HF and baseline variables for mortality, TIMI major bleeding, and combined TIMI major/minor bleeding. 
Furthermore, when testing for an interaction between assigned treatment in EUCLID and presence of HF, there were no significant interactions found.
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may be attributable to lower overall blood pressure in 
patients with PAD and HF.
Confirming our a priori hypotheses, we identify a 
clinically significant cohort of patients, those with PAD 
and concomitant HF, at potentially increased risk of 
MACEs and all- cause mortality. Furthermore, treat-
ment with antiplatelet agents including ticagrelor or 
clopidogrel was well tolerated. Finally, we identified 
increasing age, increasing weight, diabetes mellitus, 
and known CAD as the clinical attributes most strongly 
associated with development of postrandomization HF 
(defined as HF- related death or hospitalization) in pa-
tients with symptomatic PAD. These risk factors mirror 
those that are routinely referenced in the HF guidelines 
and cardiovascular disease prevention literature.13– 16 
Taken together, data from our analysis should provide 
reassurance to the practicing clinician that aggressive 
secondary prevention of atherosclerotic events with a 
single antiplatelet agent in this high- risk population is 
safe. Whether this is true for dual antiplatelet therapy 
was not studied. The high event rate in this population 
also reinforces the importance of medical therapy for 
both HF and secondary prevention of atherosclerotic 
cardiovascular disease.
Limitations
Data were not available regarding left ventricular 
ejection fraction or duration of HF. There was also 
potential risk for misclassification of HF given the 
relatively little information regarding HF disease se-
verity collected. Furthermore, there was a relatively 
low HF event rate in EUCLID, which may have been a 
result of underdetection of incident HF. This analysis 
was therefore underpowered to detect any potential 
differences. Finally, while controlling for type I error 
is important for the main findings of clinical trials, 
we have not implemented this in secondary analysis 
Table 4. Baseline Variables Associated With New- Onset HF
Baseline Variable* Categories† N
Events/100 Patient- Years Multivariable Model
(Total Events) Chi- Square HR (95% CI) P Value
Overall 10 948 0.87 (235)
Age, y ≥66 5771 1.16 (163) 34.60 1.29 (1.18– 1.40) <0.001
<66 5177 0.56 (72) Per 5 y
Weight, kg‡ ≥76 5514 1.03 (140) 29.24 0.77 (0.64– 0.93)  
Up to 60 kg, per 5
<0.001
<76 5434 0.72 (95) 1.12 (1.07– 1.16)  
Above 60 kg, per 5
Diabetes mellitus Yes 4181 1.40 (141) 19.64 1.85 (1.41– 2.43) <0.001
No 6767 0.56 (94)
Prior MI Yes 1614 1.87 (73) 15.76 1.88 (1.38– 2.56) <0.001
No 9334 0.70 (162)
GFR, mL/min per 
1.73 m2
≥76 5509 0.59 (81) 15.59 0.94 (0.91– 0.97) <0.001
<76 5439 1.17 (154) Per 5 mL/min per 
1.73 m2
Minor amputation Yes 455 2.34 (24) 14.30 2.32 (1.50– 3.59) <0.001
No 10 493 0.81 (211)
Vascular beds 3 909 2.39 (53) 11.78 1.83 (1.30– 2.59) <0.001
1 or 2 10 039 0.74 (182) 3 vs 1 or 2
Rutherford 3 or higher§ 2803 1.29 (86) 7.35 1.45 (1.11– 1.90) 0.007
Score 0– 2 8145 0.74 (149) Score ≥3 vs 0– 2
Major amputation Yes 237 2.01 (11) 6.68 2.24 (1.22– 4.14) 0.010
No 10 711 0.85 (224)
Patients without baseline HF and with complete covariate data are included (n=10 948). Variables are shown in order of decreasing model Wald chi- square 
(ie, importance in the model). ABI indicates ankle- brachial index; GFR, glomerular filtration rate; HF, heart failure; HR, hazard ratio; and MI, myocardial infarction.
*Only variables significant in the final model are shown in the table. Other variables that were assessed but were dropped from the model with P>0.05 were 
sex; geographic region; inclusion criteria (ABI or revascularization); ABI; prior carotid revascularization; tobacco use; prior percutaneous coronary intervention; 
prior coronary artery bypass grafting; prior stroke; and use of aspirin, angiotensin II receptor blocker, statin, or clopidogrel in the 30 days before enrollment.
†Continuous variables are divided at the median for the purpose of showing event rates (which require groups defined in some way) but are included in their 
continuous form in the model.
‡Weight has a nonlinear relationship with HF risk and is fit in the model as a piecewise linear spline with a single knot at 60. Over the range of weights 
up to 60 kg, the HR is 0.77 for each 5- kg increase, while over the range of weights >60 kg, the HR is 1.12 for each 5- kg increase. That is, the relationship is 
approximately V- shaped, with the highest risk of HF at the extreme weights and the lowest risk near 60 kg.
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manuscripts from EUCLID, which are considered hy-
pothesis generating.
CONCLUSIONS
Patients with symptomatic PAD and concomitant HF 
are at increased risk of MACEs and all- cause mortality 
compared with patients with PAD without HF. Despite 
worse objective and subjective measures of arterial 
disease in patients with HF, there was no difference in 
MALEs between patients with PAD stratified by pres-
ence of HF. Furthermore, treatment with antiplatelet 
agents was well tolerated with respect to bleeding 
events. These data possibly support the need for ag-
gressive treatment of recurrent atherosclerotic disease 
in patients with PAD, especially those with HF.
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Table S1. Covariates used for examining risk relationship of heart failure with outcomes. 





Demographics       
Age x x  x x x 
Female x x   x x 
Region x x x x x x 
Physical exam       
Weight x x x x  x 
Estimated GFR x x  x   
PAD history       
Incl. crit. (ABI/prior revasc) x x x x  x 
ABI x x x x  x 
Rutherford classification x x x x  x 
Major amputation x x x    
Minor amputation x x x x   




  x   
Medical history       
Tobacco use x   x   
Diabetes x x x x   
Prior PCI    x   
Prior CABG   x    
Prior MI x x  x   
Prior stroke x x  x   
Medications in 30 days prior       
ASA     x x 
ARB   x x    
Statin  x x x    
 
MACE (major adverse cardiovascular event) = Cardiovascular death, MI, or ischemic stroke 
MALE (major adverse limb event) = Major amputation or hospitalization for acute limb ischemia.  This predictor list 
is a combination of the lists from separate major amputation and acute limb ischemia models. 
For major/minor bleeding, this is a combination of the lists from separate major and minor bleeding models. 
Identification of predictors for all endpoints was carried out in the diabetes analysis, except for acute limb ischemia 
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